These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35690510)

  • 21. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
    Parnell BA; Howard JF; Geller EJ
    Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
    Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
    BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with Sacral Neuromodulation: What Are the Factors Affecting Their Therapy Satisfaction?
    Banakhar M; Hassouna M
    Urol Int; 2019; 103(4):450-453. PubMed ID: 31574517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacral neuromodulation for nonobstructive urinary retention--is success predictable?
    Goh M; Diokno AC
    J Urol; 2007 Jul; 178(1):197-9; discussion 199. PubMed ID: 17499773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment does not impact sacral neuromodulation implant rates for overactive bladder.
    Zillioux J; Lewis KC; Hettel D; Goldman HB; Vasavada SP; Gill BC
    Neurourol Urodyn; 2023 Mar; 42(3):623-630. PubMed ID: 36701189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Sacral Neuromodulation by Converting Constant Frequency Stimulation Into Variable Frequency Stimulation in Patients With Detrusor Overactivity and Impaired Contractility: A Single-Center Prospective Study.
    Zhu W; Shan S; Zhang G; Zhang Q; Zhang J; Che Y; Wen J; Wang Q
    Neuromodulation; 2023 Dec; 26(8):1836-1844. PubMed ID: 35977853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a predictive tool for sacral nerve modulation implantation in the treatment of non-obstructive urinary retention and/or slow urinary stream: a study from the Neuro-Urology Committee of the French Association of Urology.
    Nasri J; Al Ashimi I; Tricard T; Fleury R; Matta I; Bey E; Mesnard B; Gaillet S; Martin C; Game X; Thuillier C; Chartier-Kastler E; Karsenty G; Perrouin-Verbe MA; Demeestere A; Wagner L; Ruffion A; Peyronnet B; Saussine C; Phé V; Vermersch P; De Wachter S; Biardeau X
    World J Urol; 2023 Nov; 41(11):3075-3082. PubMed ID: 37783844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial experience with sacral neuromodulation for the treatment of lower urinary tract dysfunction in Brazil.
    Rios LA; Averbeck MA; Franca W; Sacomani CA; Almeida FG; Gomes CM
    Int Braz J Urol; 2016; 42(2):312-20. PubMed ID: 27176186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statewide Success of Staged Sacral Neuromodulation for the Treatment of Urinary Complaints in California (2005-2011).
    Dobberfuhl AD; Mahal A; Dallas KB; Choi KM; Comiter CV; Elliott CS
    Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):437-442. PubMed ID: 30059438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacral neuromodulation using the standardized tined lead implantation technique with a curved vs a straight stylet: 2-year clinical outcomes and sensory responses to lead stimulation.
    Vaganée D; Kessler TM; Van de Borne S; De Win G; De Wachter S
    BJU Int; 2019 May; 123(5A):E7-E13. PubMed ID: 30537223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Supervised 3 Weeks Test Phase in Sacral Neuromodulation with a 1-Year Followup.
    Tilborghs S; Van de Borne S; Vaganée D; De Win G; De Wachter S
    J Urol; 2021 Jan; 205(1):206-212. PubMed ID: 32716692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up.
    Marinkovic SP; Gillen LM; Marinkovic CM
    Neuromodulation; 2015 Aug; 18(6):517-21; discussion 521. PubMed ID: 25919573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes.
    Schober MS; Sulkowski JP; Lu PL; Minneci PC; Deans KJ; Teich S; Alpert SA
    J Urol; 2015 Dec; 194(6):1721-6. PubMed ID: 26141849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacral neuromodulation treatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a tertiary referral center in Turkey.
    Kütükoğlu MU; Altuntaş T; Şahin B; Onur AR
    Turk J Med Sci; 2023 Feb; 53(1):206-210. PubMed ID: 36945940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review.
    Martin S; Zillioux J; Goldman HB
    Neurourol Urodyn; 2022 Apr; 41(4):955-961. PubMed ID: 35238421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
    Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
    Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic effects of sacral neuromodulation on detrusor underactivity].
    Wang Q; Zhang WY; Liu XH; Wang MR; Lai JH; Hu H; Xu T; Xu KX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):671-674. PubMed ID: 34393226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.